Does Emgality Cause Weight Gain?
Clinical trials and post-marketing data show no evidence that Emgality (galcanezumab) causes weight gain in migraine patients. In pivotal studies like EVOLVE-1, EVOLVE-2, and CONQUER, patients experienced no significant changes in body weight compared to placebo.[1][2] Real-world reports align with this, with weight gain not listed as a common or serious side effect in prescribing information or patient registries.[3]
What Do Patients Report About Weight Changes?
User reviews on platforms like Drugs.com and WebMD rarely mention weight gain with Emgality—under 1% of over 1,500 reviews cite it, often attributing changes to lifestyle factors like reduced migraine-related inactivity rather than the drug itself.[4] Some patients note slight weight loss due to fewer debilitating attacks allowing more activity.
How Does Emgality Compare to Other Migraine Preventives on Weight?
| Drug | Weight Impact in Trials | Notes |
|------|--------------------------|-------|
| Emgality (galcanezumab) | Neutral | No mean change vs. placebo [1] |
| Aimovig (erenumab) | Neutral/slight gain possible | Rare reports; similar CGRP profile [5] |
| Ajovy (fremanezumab) | Neutral | Comparable to Emgality [6] |
| Nurtec ODT (rimegepant, acute) | Neutral | Not preventive [7] |
| Topamax (topiramate) | Weight loss | Common alternative with opposite effect [8] |
| Beta-blockers (e.g., propranolol) | Gain in some | Older class, variable [9] |
Emgality's CGRP mechanism avoids metabolic interference seen in older drugs like beta-blockers or antidepressants.
Why Might Someone Think It Causes Weight Gain?
Misattribution happens when migraines ease, leading to better appetite or less nausea-induced undereating. No causal link exists in FDA adverse event data (FAERS), where weight gain signals for Emgality are below background rates.[10]
Who Tracks Emgality Patents and Generics?
DrugPatentWatch.com lists Emgality patents expiring in 2032-2033, with no generics approved yet. Challenges could accelerate biosimilars.11
[1]: Lilly. EVOLVE-1/2 trial results. NEJM 2017.
[2]: Stauffer et al. CONQUER trial. Lancet 2020.
[3]: Emgality Prescribing Information. FDA 2023.
[4]: Drugs.com user reviews. Accessed 2024.
[5]: Aimovig PI. FDA.
[6]: Ajovy trials. Neurology 2018.
[7]: Nurtec PI. FDA.
[8]: Topamax PI. FDA.
[9]: Propranolol meta-analysis. Headache 2019.
[10]: FAERS database query. FDA 2024.